

Muscarinic Acetylcholine Receptor M4 (CHRM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M5D15068B7EFEN.html>

Date: May 2022

Pages: 75

Price: US\$ 3,500.00 (Single User License)

ID: M5D15068B7EFEN

Abstracts

Muscarinic Acetylcholine Receptor M4 (CHRM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 20 molecules. Out of which approximately 20 molecules are developed by Companies. The latest report GMDHC22094TDB - Muscarinic Acetylcholine Receptor M4 - Drugs In Development, 2022, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3, 12 and 1 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Ophthalmology and Undisclosed which include indications Schizophrenia, Alzheimer's Disease, Psychosis, Parkinson's Disease, Angelman Syndrome, Cognitive Impairment

Associated With Schizophrenia (CIAS), Drug-Induced Dyskinesia, Dyskinesia, Fragile X Syndrome, Infantile Spasm (West Syndrome), Neurology, Presbyopia, Rett Syndrome, Tuberous Sclerosis, Unspecified Neurologic Disorders, Unspecified Psychiatric Disorders and Unspecified Rare Disease.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Anavex Life Sciences Corp

AstraZeneca Plc

Cerevel Therapeutics Holdings Inc

Karuna Therapeutics Inc

Lan Sheng Biomedicine Suzhou Co Ltd

Lenz Therapeutics LLC

MapLight therapeutics Inc

Neumora Therapeutics Inc

Neurocrine Biosciences Inc

NeuroSolis Inc

Sosei Group Corp

Suven Life Sciences Ltd

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles

(aceclidine + tropicamide) - Drug Profile

(trospium chloride + xanomeline) - Drug Profile

blarcamesine hydrochloride - Drug Profile

emraclidine - Drug Profile

HTL-0016878 - Drug Profile

Lead Optimization - Drug Profile

LS-001 - Drug Profile

M4 PAMs for Schizophrenia and Other Psychosis - Drug Profile

ML-007 - Drug Profile

NMRA-M4R - Drug Profile

NSX-0527 - Drug Profile

NSX-0527f - Drug Profile

NSX-0559 - Drug Profile

NSX-0559f - Drug Profile

Small Molecule to Agonize Muscarinic Acetylcholine Receptor M4 for Schizophrenia - Drug Profile

Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Unspecified Neurologic Diseases - Drug Profile

Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile

VU-0467154 - Drug Profile

VU-6000918 - Drug Profile

VU-6001852 - Drug Profile

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Addex Therapeutics Ltd, 2022

Pipeline by Anavex Life Sciences Corp, 2022

Pipeline by AstraZeneca Plc, 2022

Pipeline by Cerevel Therapeutics Holdings Inc, 2022

Pipeline by Karuna Therapeutics Inc, 2022

Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, 2022

Pipeline by Lenz Therapeutics LLC, 2022

Pipeline by MapLight therapeutics Inc, 2022

Pipeline by Neumora Therapeutics Inc, 2022

Pipeline by Neurocrine Biosciences Inc, 2022

Pipeline by NeuroSolis Inc, 2022

Pipeline by Sosei Group Corp, 2022

Pipeline by Suven Life Sciences Ltd, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

I would like to order

Product name: Muscarinic Acetylcholine Receptor M4 (CHRM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M5D15068B7EFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M5D15068B7EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

